Treatment results and events observed in the 500 adult patients with HL in CS IA and IIA included in the H81 and H90 trials
. | Group A . | Group B . | Group C . | All . |
|---|---|---|---|---|
| No. patients submitted to CT | 42 | 144 | 314 | 500 |
| 1 mo, no. (ABVD, no./EBVM, no.) | 23 (18/5) | 68 (51/17) | 0 | 91 |
| 3 mo, no. (ABVD, no./EBVM, no.) | 17 (12/5) | 73 (56/17) | 296 (212/84) | 386 |
| 3 mo 7-drug CT, no. | 2 | 3 | 18 | 23 |
| Results of CT | ||||
| CR, no* | 40* | 126* | 236 | 402 |
| PR, no. | 2 | 16 | 69 | 87 |
| Failure of CT, no. | 0 | 2 | 9 | 11 |
| No. patients submitted to RT | 42 | 142 | 305 | 489 |
| Supradiaphragmatic disease, no. | 31 | 124 | 305 | 460 |
| Infradiaphragmatic disease, no. | 11 | 18 | 0 | 29 |
| Results of RT | ||||
| CR after RT, no. | 41 | 142 | 305 | 488 |
| Failure of RT, no. | 1 | 0 | 0 | 1 |
| No. patients submitted to salvage therapy | 1 | 2 | 9 | 12 |
| No. after failure of CT/no. RT | 0/1 | 2/0 | 9/0 | 11/1 |
| Alive with sustained CR, no. | 0 | 1 | 6 | 7 |
| Deceased in CR, no. | 0 | 1 | 0 | 1 |
| Deceased with active disease, no. | 1 | 0 | 3 | 4 |
| No. patients in CR at completion of combined modality treatment | 41 | 142 | 305 | 488 |
| Alive with sustained first CR, no. | 32 | 117 | 254 | 403 |
| Deceased in first CR, no. | 3 | 16 | 20 | 39 |
| Relapsing after first CR, no. | 6 | 9 | 31 | 46 |
| Final outcome, no. | 42 | 144 | 314 | 500 |
| Alive with sustained CR, no. | 38 | 125 | 278 | 441 |
| Deceased with HL, no. | 1 | 1 | 14 | 16 |
| Deceased in CR, no. | 3 | 18 | 22 | 43 |
. | Group A . | Group B . | Group C . | All . |
|---|---|---|---|---|
| No. patients submitted to CT | 42 | 144 | 314 | 500 |
| 1 mo, no. (ABVD, no./EBVM, no.) | 23 (18/5) | 68 (51/17) | 0 | 91 |
| 3 mo, no. (ABVD, no./EBVM, no.) | 17 (12/5) | 73 (56/17) | 296 (212/84) | 386 |
| 3 mo 7-drug CT, no. | 2 | 3 | 18 | 23 |
| Results of CT | ||||
| CR, no* | 40* | 126* | 236 | 402 |
| PR, no. | 2 | 16 | 69 | 87 |
| Failure of CT, no. | 0 | 2 | 9 | 11 |
| No. patients submitted to RT | 42 | 142 | 305 | 489 |
| Supradiaphragmatic disease, no. | 31 | 124 | 305 | 460 |
| Infradiaphragmatic disease, no. | 11 | 18 | 0 | 29 |
| Results of RT | ||||
| CR after RT, no. | 41 | 142 | 305 | 488 |
| Failure of RT, no. | 1 | 0 | 0 | 1 |
| No. patients submitted to salvage therapy | 1 | 2 | 9 | 12 |
| No. after failure of CT/no. RT | 0/1 | 2/0 | 9/0 | 11/1 |
| Alive with sustained CR, no. | 0 | 1 | 6 | 7 |
| Deceased in CR, no. | 0 | 1 | 0 | 1 |
| Deceased with active disease, no. | 1 | 0 | 3 | 4 |
| No. patients in CR at completion of combined modality treatment | 41 | 142 | 305 | 488 |
| Alive with sustained first CR, no. | 32 | 117 | 254 | 403 |
| Deceased in first CR, no. | 3 | 16 | 20 | 39 |
| Relapsing after first CR, no. | 6 | 9 | 31 | 46 |
| Final outcome, no. | 42 | 144 | 314 | 500 |
| Alive with sustained CR, no. | 38 | 125 | 278 | 441 |
| Deceased with HL, no. | 1 | 1 | 14 | 16 |
| Deceased in CR, no. | 3 | 18 | 22 | 43 |
Fourteen patients (3 in group A, 11 in group B) with peripheral CS IA were in apparent CR before starting CT.